Nidec Corporation

Ongoing structural reforms targeting a ¥100 billion reduction in variable costs and ¥50 billion in fixed costs through business consolidation, site rationalization, and exit from low-margin segments are expected to materially improve operating margins and net profitability, especially into FY2027, supporting a significant rerating of the business.

Execution risk around large-scale cost cuts and R&D reorganization, compounded by ongoing investigations into accounting and trade compliance, could quickly undermine confidence in margin recovery projections and derail the structural reform narrative before it delivers tangible results.

A DCF model points to an intrinsic value of ¥3,609.40 per share, implying a 22.8% discount to Nidec's trading price, with Goldman Sachs maintaining a Buy rating and a ¥3,200 price target — suggesting the market has yet to fully price in Nidec's long-term cash flow generation capacity.

A narrative-based fair value estimate of ¥2,596.25 places Nidec 7.3% overvalued at recent prices, while JPMorgan maintains a Sell rating with a ¥1,800 price target. The stock's 5-year total shareholder return, down 53.79%, casts doubt on management's ability to create sustained shareholder value.

Despite receiving a regulatory extension for its Annual Securities Report filing due to internal investigations into product quality and improper conduct, Nidec's shares posted a 4.07% 1-day return and a 9.59% 7-day return, indicating that investors may view the transparency of the investigation process as a net positive for long-term governance.

The delay in Nidec's Annual Securities Report filing, driven by unresolved probes into product quality issues and improper conduct, introduces material uncertainty. Analyst sentiment remains divided, with a broad price target range from ¥1,800 to ¥3,500, reflecting deep disagreement about how these risks could affect future earnings and credibility.